Skip to main content

Table 3 EORTC QLQ-C30 symptom domains and time point of questionnaire completion (54 patients, 561 QOL assessments)

From: Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden

EORTC QLQ-C30 At the hospital At home (1 week later) At home (2 weeks later) Time point (main effect) F/p values
Estimated mean (95% CI)  
Fatigue 34.2 1w, 2w(29.2-39.3) 43.3 Ho, 2w (38.2-48.3) 39.8 Ho, 1w (34.4-45.1) F = 21.40; p < 0.001
Nausea/Vomiting 6.1 1w(3.3-8.9) 12.7 Ho, 2w (9.8-15.5) 8.3 1w(5.2-11.4) F = 19.89; p < 0.001
Pain 18.7(13.5-24.0) 21.7(16.4-27.0) 21.6(16.0-27.1) F = 2.51; p = 0.083
Dyspnoea 22.8 1w(16.1-29.5) 26.3 Ho, 2w(19.6-33.1) 22.9 1w(16.0-29.8) F = 3.92; p = 0.021
Sleeping Disturbances 26.0 1w(20.1-32.0) 34.4 Ho, 2w (28.4-40.5) 29.6 1w(23.3-36.0) F = 12.37; p < 0.001
Appetite Loss 12.8 1w(7.5-18.1) 21.7 Ho, 2w (16.4-27.1) 15.6 1w(9.9-21.3) F = 14.94; p < 0.001
Constipation 13.3 1w, 2w(8.1-18.5) 23.1 Ho (17.8-28.4) 19.4 Ho (13.7-25.2) F = 13.70; p < 0.001
Diarrhoea 7.1(4.1-10.2) 7.3(4.2-10.3) 6.0(2.6-9.3) F = 0.46; p = 0.634
Financial Impact 16.6(10.5-22.7) 18.4(12.3-24.5) 18.9 (12.6-25.1) F = 2.94; p = 0.054
  1. superscript numbers indicate significance (p < 0.05) of post-hoc group comparisons (LSD-test).
  2. score differences to the hospital-based assessment exceeding 5 points are given in bold letters.